ImmunityBio Clocks 700% Revenue Surge In 2025 From Lead Bladder Cancer Drug

ImmunityBio, Inc. (NASDAQ:IBRX) shares are up on Thursday as the company is reporting continued execution and sales momentum, with a significant increase in preliminary net product revenue.IBRX Reports 700% Revenue Surge in 2025ImmunityBio announced preliminary net product revenue for Anktiva reached approximately $113 million for fiscal 2025, reflecting a remarkable 700% increase year-over-year.Anktiva is the first FDA-approved immunotherapy for non-muscle invasive bladder cancer carcinoma in situ (CIS).Fo ...